What Destiny Pharma does

Destiny Pharma plc is a UK-based, publicly traded clinical-stage biotechnology company listed on AIM (ticker: DEST), headquartered in Brighton and founded in 1996. The company develops novel anti-infective drugs targeting drug-resistant bacterial infections, with its primary asset being XF-73, a proprietary drug candidate under investigation for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. Since July 2022, XF-73 development has included a cystic fibrosis-focused sub-program supported by a Cystic Fibrosis Foundation award, using clinical isolates from CF patients to assess real-world effectiveness against MRSA — a population with elevated infection risk.

The company's core technology is XF-73 itself, positioned as a novel-method anti-infective compound in a competitive anti-MRSA landscape that includes over 25 active companies developing more than 27 pipeline therapies. There is no evidence of in-licensed platform technology, combination products, or a broader pipeline beyond XF-73 in the available data. The small headcount (11–50 employees) and focus on a single asset is consistent with a single-asset clinical developer.

As a clinical-stage biopharmaceutical, Destiny Pharma does not generate product revenue. Capital has historically been sourced through AIM-listed equity financings and venture rounds, with named investors including Longbow Capital (2008), ACF Investors and Juno Capital Partners (2014), China Medical System Holdings and Downing Ventures (2017), CMS Medical Venture Investment and Downing LLP (2017), and an Antimicrobial Resistance-linked 2019 round. The most recent capital event (March 2023) raised approximately £7.34 million (~$8.89 million) via ~20.96 million new shares, bringing total issued shares to ~94.46 million. Upon any future regulatory approval, commercial distribution would likely proceed through established pharmaceutical supply chains and specialty pharmacy networks, though no commercial GTM motion is currently in place.

Name

Destiny Pharma

Legal name

Destiny Pharma plc

Website

https://destinypharma.com

Company type

Public

Founded year

1996

Operating status

Operating

Headcount range

11–50 employees

Short description

Destiny Pharma plc is a UK-based, AIM-listed clinical-stage biopharmaceutical company developing XF-73, a proprietary anti-infective drug candidate for MRSA infections, with a focused expansion into cystic fibrosis patients via a Cystic Fibrosis Foundation-supported program.

Ownership category

akta.pro rank

Product category

Anti-infective Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Antimicrobial drug development
• Clinical-stage biopharmaceuticals
• MRSA infection treatment
• Cystic fibrosis therapeutics
• Anti-infective pharmaceuticals

Headquarters

HQ city

Brighton

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Destiny Pharma plc is a clinical-stage biopharmaceutical company developing novel antimicrobial drugs, with its lead candidate XF-73 designed for nasal decolonization of methicillin-resistant Staphylococcus aureus (MRSA) in cystic fibrosis patients. The company focuses on developing anti-resistance therapies to address drug-resistant bacterial infections. Founded in 1996 and headquartered in Brighton, UK, the company operates with 11–50 employees.

Product overview

Destiny Pharma is a clinical-stage biotechnology company focused on developing novel anti-infective drugs. The company's primary product candidate is XF-73, a drug being investigated for the treatment of MRSA infections in cystic fibrosis patients, with research supported by the Cystic Fibrosis Foundation. The company operates in the biotechnology/pharmaceutical sector developing drug candidates rather than software products or platforms.

Differentiator

Problem solved

Functional benefit

Products and services

• XF-73 XF-73 is Destiny Pharma's lead clinical-stage drug candidate — a porphyrin-based novel antimicrobial — designed for nasal decolonization of methicillin-resistant Staphylococcus aureus (MRSA) in patients with cystic fibrosis. It targets the hospital-acquired infection and antimicrobial resistance market.

Quantifiable outcome

• XF-73 drug candidate under investigation for MRSA treatment in cystic fibrosis patients through clinical isolate studies

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Nabriva Therapeutics: Develops Xenleta (lefamulin), an antibiotic for community-acquired bacterial pneumonia. Comparable small-cap anti-infective company with similar regulatory pathway and MRSA-adjacent positioning.
• Motif Bio: Developed iclaprim, an antibiotic targeting MRSA and other Gram-positive infections. Closely comparable small-cap clinical-stage anti-MRSA developer with similar profile to Destiny's XF-73 program.
• Melinta Therapeutics: Markets Baxdela (delafloxacin), an antibiotic approved for acute bacterial skin and skin-structure infections including MRSA. Comparable as a small-cap anti-infective commercial-stage company focused on resistant Gram-positive infections.
• Paratek Pharmaceuticals: Develops Nuzyra (omadacycline), an FDA-approved antibiotic with MRSA activity. Direct competitor in the anti-infective space targeting similar resistant-infection indications, with overlapping commercial and regulatory pathway.
• Iterum Therapeutics: Clinical-stage company developing oral antibiotics (sulopenem) for resistant infections including MRSA. Comparable as a small-cap, single-asset anti-infective developer at similar clinical stage.

Emerging players

• ContraFect Corporation: Develops direct lytic agents and other therapies for serious infections including MRSA. Comparable as a clinical-stage anti-infective company focused on resistant bacterial infections.
• Summit Therapeutics: UK-based clinical-stage biotech developing anti-infective therapies including ridinilazole for C. difficile. Comparable as a UK-listed small-cap anti-infective developer with similar operational profile.
• BioVersys: Swiss clinical-stage company developing small-molecule anti-infectives addressing antimicrobial resistance. Comparable as a small-cap clinical-stage AMR-focused developer with similar therapeutic approach.

Regional players

• Helperby Therapeutics: UK-based clinical-stage company developing antibiotic resistance breakers to potentiate existing antibiotics. Comparable as a UK-based clinical-stage anti-infective developer addressing the same AMR challenge.

Broad incumbents

• Tetraphase Biosciences: Developed Xerava (eravacycline), a fluorocycline antibiotic approved for complicated intra-abdominal infections. Comparable as an anti-infective commercial-stage peer acquired by La Jolla Pharmaceutical, illustrating the small-cap anti-infective M&A pathway available to Destiny.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/destinypharma
• LinkedInlinkedin.com/company/destiny-pharma-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds7 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Destiny Pharma